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ABSTRACT
Objective We aimed to delineate the neurodevelopmental
spectrum associated with SYNGAP1 mutations and to
investigate genotype–phenotype correlations.
Methods We sequenced the exome or screened the exons
of SYNGAP1 in a total of 251 patients with
neurodevelopmental disorders. Molecular and clinical data
from patients with SYNGAP1 mutations from other centres
were also collected, focusing on developmental aspects and
the associated epilepsy phenotype. A review of SYNGAP1
mutations published in the literature was also performed.
Results We describe 17 unrelated affected individuals
carrying 13 different novel loss-of-function SYNGAP1
mutations. Developmental delay was the first manifestation
of SYNGAP1-related encephalopathy; intellectual disability
became progressively obvious and was associated with
autistic behaviours in eight patients. Hypotonia and unstable
gait were frequent associated neurological features. With the
exception of one patient who experienced a single seizure,
all patients had epilepsy, characterised by falls or head drops
due to atonic or myoclonic seizures, (myoclonic) absences
and/or eyelid myoclonia. Triggers of seizures were frequent
(n=7). Seizures were pharmacoresistant in half of the
patients. The severity of the epilepsy did not correlate with
the presence of autistic features or with the severity of
cognitive impairment. Mutations were distributed throughout
the gene, but spared spliced 30 and 50 exons. Seizures in
patients with mutations in exons 4–5 were more
pharmacoresponsive than in patients with mutations in
exons 8–15.
Conclusions SYNGAP1 encephalopathy is characterised
by early neurodevelopmental delay typically preceding the
onset of a relatively recognisable epilepsy comprising
generalised seizures (absences, myoclonic jerks) and frequent
triggers.
INTRODUCTION
The human SYNGAP1 gene on chromosome
6p21.3 encodes the synaptic RAS-GTPase-activating
protein 1, a protein of the post-synaptic density
(PSD) of glutamatergic neurons.1 2 SYNGAP1 inter-
acts with PSD95 (DLG4) and SAP102 (DLG3), and is
able to positively or negatively regulate the density of
N-Methyl-D-aspartic acid (NMDA) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors at the glutamatergic synapses and mediate
signalling downstream of glutamate receptor activa-
tion.3 4 While complete Syngap1 deficiency in mice is
lethal at early postnatal stages, heterozygous syngap1
+/- mice are viable but show behavioural and cogni-
tive disturbances.5–8 Syngap1 haploinsufficiency dis-
rupts the excitatory/inhibitory balance in the
developing hippocampus and cortex and results in
accelerated glutamatergic synapse maturation. When
this process occurs during critical developmental
windows, it alters the synaptic plasticity necessary for
the refinement of connections that ultimately shape
cognitive and behavioural modalities.4 9 Different
SYNGAP1 protein isoforms exist and are generated
through alternative splicing and alternative promoter
usage, in a process regulated by synaptic activity and
postnatal age in mice. Two of the main SYNGAP1
mouse isoforms that differ in their N-terminal and C-
terminal sequences have opposite effects on glutam-
ate activation pathway.10 Although several isoforms
have also been described in humans, their specific
role has not yet been established.
Recently, several groups have independently
reported de novo SYNGAP1 mutations in patients
with intellectual disability (ID), epileptic encephal-
opathy (EE) or autism spectrum disorders (ASD)
identified by exome sequencing11–15 or direct
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sequencing of the SYNGAP1 gene through a candidate gene
approach.16–24 Recently, seven SYNGAP1 mutations were identi-
fied by exome sequencing in a series of 1133 patients, 83% of
whom had ID, indicating a frequency of SYNGAP1 mutation of
∼0.74% in patients with ID.25 One patient with a chromosomal
translocation interrupting SYNGAP126 and five patients with
6p21.3 deletions encompassing SYNGAP123 27–30 have also
been reported. Thus, to date, SYNGAP1 appears one of the
most relevant ID-causing genes, with mutations possibly
explaining 0.7 to 1% of ID. Genotype–phenotype correlations
have not been clearly established. Moreover, because most
patients with SYNGAP1 mutation were identified in large-scale
exome or panel studies, the clinical features and the natural
history of the SYNGAP1-associated ID and epilepsy remain to
be precisely described. Here, we have gathered the molecular
and clinical data of 15 unreported and two previously reported




We analysed 251 patients with variable neurodevelopmental phe-
notypes including ID, EE and ASD (see online supplementary
methods for details) by exome sequencing (n=59) or direct
sequencing of genes encoding synaptic proteins (n=192). One
additional patient had an intragenic SYNGAP1 deletion identi-
fied by microarray-based comparative genomic hybridisation
(array-CGH). Clinical and molecular data of 13 additional
patients with SYNGAP1 mutation, identified in 12 other centres,
were collected: all patients with a mutation introducing a prema-
ture termination codon or occurring de novo (ie, proven patho-
genic), with the exception of patients with genomic deletions
encompassing other genes than SYNGAP1, were eligible for inclu-
sion. Patients #2 and #10 have been previously reported.12 24
Each patient’s referring physician filled out a table with detailed
developmental, neurological, behavioural and epilepsy history,
including EEG and imaging data if available. Most patients were
evaluated according to developmental scales routinely used in
enrolled centres by clinicians trained in neurodevelopment or
neuropsychologists (eg, Brunet-Lezine, HAWIK-IV or SON-R2
scales). The sex ratio was eight males/nine females. Mean age at
the time of the study was 10.3 years (range 3–29 years).
Exome sequencing
The exome of index cases or parent–offspring trios was
sequenced by IntegraGen (Evry, France) or by the Genotypic
and sequencing facility of ICM.31 Exons were captured from
fragmented genomic DNA samples using the SureSelect Human
All Exon 50 Mb exome kit (Agilent Technologies) or the
SeqCap EZ Solution-Based Enrichment V.3.0 (Roche), and
paired-end 150-base massive parallel sequencing was carried out
on an Illumina HiSeq2500 or a NextSeq500, according to man-
ufacturers’ protocols. Bioinformatics analyses were respectively
done using the in-house pipeline developed by Integragen SA,
as previously described,31 or by the iCONICS ICM facility plat-
form as follows: sequencing reads passing quality filtering were
aligned to the human reference genome (hg19) with Burrows–
Wheeler aligner (BWA);32 GATK33 was used to recalibrate base
quality scores, realign around indels and mark duplicate reads.
Variants were filtered based on their impact on the gene (mis-
sense, nonsense, frameshift, splice site-altering variants) and a
minor allele frequency <1% in databases (Exome Variant
Server, 1000 Genomes, HapMap, Exome Aggregation
Consortium and in-house databases). Calling of de novo variants
in trios was done using the Eris interface (Integragen SA) or
Polyweb (University Paris-Descartes).
SYNGAP1 screening and Sanger sequencing
All exons and intron–exon junctions of SYNGAP1
(NM_006772.2) and 18 other synaptic genes were amplified
using the Fluidigm Access Array technology (IFC Controller
AX, FC1 Cycler, 48×48 Access Arrays) and sequenced on a
MiSeq Illumina sequencer as paired-end 2×250 bp reads.
Alignment of reads on the human reference was performed with
BWA and GATK, and additional bioinformatics steps including
filtering for novel coding variants were done using an in-house
pipeline. Mutations identified by next-generation sequencing
(exome or panel) were validated by Sanger sequencing. De novo
occurrence was tested by analysing available parents. The pre-
dicted effect of mutations was interpreted with Alamut 2.2
(Interactive Biosoftware).
SYNGAP1 isoforms and genotype–phenotype correlations
Human SYNGAP1 cDNA and protein sequences were retrieved
from NCBI and Uniprot, aligned using Clustalw2 (http://www.
ebi.ac.uk/Tools/msa/clustalw2/) and compared with mouse and
rat isoforms.10 We first assessed genotype–phenotype correla-
tions in the 17 affected individuals from our cohort.
Review of individuals with previously published SYNGAP1
mutations
The terms ‘SYNGAP1’ and ‘mutation’ were used to search for
articles reporting patients with SYNGAP1 mutation in PubMed.
In addition, SYNGAP1 mutations and variants present in the
HGMD professional (Biobase) and Exac databases were
retrieved, listed and visualised on the schematic representation
of the SYNGAP1 gene. Statistical analysis was done using the
Fisher exact test.
RESULTS
Genetic analyses and review of SYNGAP1 mutations
In our cohort of 251 patients with neurodevelopmental disor-
ders, we identified 3 patients (1.2%) with novel de novo patho-
genic heterozygous mutations of SYNGAP1 using exome or
panel sequencing. One additional patient had a SYNGAP1 dele-
tion of 16.6 kb encompassing exons 2–9, identified by
array-CGH. We collected additional phenotypic information for
2 cases published previously12 24 and 11 additional patients
with SYNGAP1 mutations identified in other centres (see table 1
and online supplementary table S2).
SYNGAP1 mutations occurred de novo in all 12 patients for
whom DNA of both parents was available and, with the excep-
tion of one de novo missense mutation, all of them introduced a
premature termination codon in the protein sequence (table 1
and figure 1). None of the mutations were reported in control
databases (Exome Variant Server, 1000Genomes, HapMap,
Exome Aggregation Consortium). The single missense mutation
of this study (c.1685C>T, p.Pro562Leu, rs397514670), also
identified in a previously reported patient,20 altered a highly
conserved amino acid of the RasGap/GTPase domain of the
protein (up to yeast) and was predicted damaging by SIFT and
PolyPhen-2.
In total, 47 patients (including two monozygotic twins23) car-
rying 43 different point mutation or indels limited to the
SYNGAP1 gene have been described to date (figure 1 and online
supplementary table S3). Three recurrent mutations
(c.321_324del, c.427C>T/p.Arg143*, c.1685C>T/p.Pro562Leu)
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Table 1 Molecular and clinical data from the 17 patients with SYNGAP1 mutations*
Patient ID 1 2 3 4 5 6 7 8 9
Age at the time of the study (years) 14 15 8.5 10.8 15 11 5 9.8 5.5
Sex M F F M F M F F F
Ancestry Guinean European European European Moroccan Malian European European European
Genetics
Mutation type Intragenic deletion Nonsense Nonsense Nonsense Frameshift Nonsense Splice site Frameshift Frameshift
Mutation c.68–1518-?_1530+?del c.348C>A c.403C>T c.427C>T c.455_459del c.490C>T c.509+1 G>T c.828dup c.1057delC
Protein level p.? p.Tyr116* p.Arg135* p.Arg143* p.Arg152Glnfs*14 p.Arg164* p.? p.Lys277Glnfs*7 p.Leu353Trpfs*13
Location in gene Intron 1—exon 9 Exon 4 Exon 5 Exon 5 Exon 5 Exon 5 Intron 5 Exon 8 Exon 8
Inheritance De novo De novo De novo De novo De novo De novo De novo Parents not tested Parents not tested
Level of intellectual




10.8 years Severe/11 years Severe/11 years Moderate/5 years
Moderate/
4.5 years Moderate/5.5 years
Developmental stages











Age of first words/first
sentences





4 years transient ‘mama’
‘papa’/no sentences
NA/no sentences 3 years/5 years 23 months 36 months/no
sentences
Current language ability Single words NA ∼50 words 10 words Absence of speech Few words at 11 years 5-word sentences Short sentences 15 words





No No No Possible (loss of few
acquired words)




Autism spectrum disorder No Yes No Yes Yes Yes No No No
Clinical examination
Age at examination 14 years 12 years 5.5 years 10.8 years 11 years 10 years 5 years 6 years 5.5 years
Height in cm (SD)/weight
in kg (SD)/head




















Nystagmus during the 1st











Patient ID 10 11 12 13 14 15 16 17 Summary
Age at the time of the study (years) 5 3 22 12 8 8.2 29 10 Mean 11.4
Sex M M F M F M M M M=8, F=9
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Table 1 Continued
Patient ID 10 11 12 13 14 15 16 17 Summary
Genetics
Mutation type Nonsense Nonsense Missense Nonsense Frameshift Frameshift Frameshift Splice site Nonsense 7;
frameshift 5; splice 2;
missense 1; intragenic
deletion 1
Mutation c.1253_1254del c.1630C>T c.1685C>T c.1995T>A c.2214_2217del c.2933del c.3406dup c.3408+1G>A
Protein level p.Lys418Argfs*54 p.Arg544* p.Pro562Leu p.Tyr665* p.Glu739Glyfs*20 p.Pro978Hisfs*99 p.Gln1136Profs*17 p.?
Location in gene Exon 8 Exon 10 Exon 11 Exon 12 Exon 13 Exon 15 Exon 15 Intron 15
Inheritance De novo De novo De novo Parents not tested De novo De novo Parents not tested De novo
Level of intellectual disability/age
at evaluation Severe/4 years Severe/3 years Severe/22 years
Severe/
12 years Mild/8 years
Moderate/
5 years Severe/8.5 years Severe/10 years
Mild n=2; moderate n=5;
severe n=10/mean age at
evaluation 8.7 years
Developmental stages





























Mean age first words
2.6 years






120 words, 3- to
4-word sentences
5 words Absence of speech Absence of
speech
Absence of speech 7;
speaks words 5;
associates words or simple
sentences 3
Regressive episode during the
development/age
Since age of 36 months
loss of ‘mama’, ‘papa’
No 12 months—with
febrile seizures





Autism spectrum disorder Yes
Too young to
be evaluated No No Yes No Yes Yes Yes 8; no 8
Clinical examination
Age at examination 5.2 years 3 years 22 years 12 years 8 years 7 years 8.5 years 6.6 years Mean 8.9 years
Height in cm (SD)/weight in kg







































dystonic postures of hands


















*Patients are ordered by mutation from the 50 end of the gene.
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were found in two patients each. Pathogenic mutations in
SYNGAP1 are distributed throughout the gene, especially in
exons 5, 8 and 15, which are among the largest exons of
SYNGAP1. Interestingly, the two first and two last exons, which
are alternatively spliced and included in 3 out of 5 SYNGAP1 iso-
forms, but also exons 9 and 16, present in all known isoforms
seem to be spared (figure 1).
Clinical and neurodevelopmental features of
SYNGAP1-related encephalopathy
All patients with SYNGAP1 anomalies of our series had ID,
which was evaluated as severe in 10 patients, moderate in 5 and
mild in 2 (see table 1 and online supplementary table S1). The
mean age of sitting unsupported was 12 months (median age
10 months, n=15) and of walking 27.7 months (median age 24
months, n=15). Also, 10/17 patients could walk by age 2 years
and 14/17 by age 3 years. All patients had speech delay: 12 of
them spoke first words at a mean age of 2.5 years and 5 patients
did not speak at age 10 years or older. In most patients, both
receptive and expressive languages were affected. Two patients
had mild ID, including one without motor delay. In those, mild,
progressive language delay and behavioural anomalies were the
most prominent features.
In total, 8 out of 16 patients (50%) older than 3 years old
were diagnosed with ASD. Patients with ASD had remarkably
poor verbal and non-verbal communication abilities as well as
impaired social interactions (see online supplementary table S1).
Half of the patients (n=4/8) with severe ID, 1/5 with moderate
ID and 2/2 with mild ID were diagnosed with ASD.
Independent from a formal diagnosis of ASD, many of the
patients exhibited stereotypies (n=10), temper tantrums, aggres-
siveness, self-injurious behaviour and/or restlessness (n=7).
Neurological examination, performed at a mean age of
8.9 years, was considered normal in two patients. Gait was
clumsy or unsteady in five patients and ataxic in five others.
Truncal hypotonia was reported in 10 patients and facial hypo-
tonia in 4. Some patients had orthopaedic problems, such as pes
planus and rotation of the hips.
Brain MRI performed in all 17 patients (mean age 5.4 years)
was either normal or revealed nonspecific features (arachnoid
cysts in two patients, mild myelination delay in one and signal
abnormities in another).
Epilepsy was diagnosed in 16/17 patients (table 2). The only
patient without epilepsy, who was aged 5 at the time of this
study, had a single afebrile seizure at the age of 3.5 years.
Excluding this patient, first seizures occurred at a mean age of
3 years (range 1–8 years) and consisted of drop attacks, massive
myoclonic jerks, atonic seizures, myoclonic absences or
absences. A diagnosis of myoclonic astatic epilepsy (MAE, ie,
Doose syndrome) and epilepsy with myoclonic absences (EMAs)
was made in three and one patients, respectively. The others
were diagnosed with unclassified genetic generalised epilepsy
(GGE). None had a diagnosis of Lennox–Gastaut syndrome
(LGS).
The epilepsy responded to a single antiepileptic drug (AED),
mostly sodium valproate, in seven patients and was pharmacore-
sistant in nine (list of AEDs is reported in table 2). During the
active phases of epilepsy, seizures occurred daily in five patients,
10 times per day or more in two and 100 times daily or more in
two others. Seizures were of short duration, and the most fre-
quent seizure types were typical or atypical absences (n=9),
massive myoclonic jerks with or without falls (n=7), eyelid
myoclonia (n=3), clonic or tonic clonic seizures (n=3), myo-
clonic absences (n=3) and atonic seizures (n=2). Head drops or
falls were relatively frequent (n=5) and reported as myoclonic
astatic, atonic seizures or drop attacks. Eight patients had several
seizure types. No patient had status epilepticus, and exacerba-
tion by fever was mentioned in four. We found no correlations
between the diagnosis of ASD and the age at epilepsy onset.
The proportion of patients with ASD was identical among those
with pharmacoresistant (n=5/10) and pharmacosensitive epi-
lepsy (n=3/6).
The most frequent anomalies reported on EEG traces (figure 2)
from 16 patients were ictal or interictal bursts of spikes, spike
waves or slow waves that were either generalised (n=13), general-
ised with a posterior predominance or posterior only (n=5).
Paroxysmal anomalies were localised to central regions in six
instances. Triggers of seizures were identified in seven patients,
including photosensitivity (PS, n=5), fixation-off sensitivity (FOS,
n=1), PS and FOS (n=1) and chewing (n=1).
Genotype/phenotype correlations
We observed no definite correlation between the location of the
mutation on the gene and the severity of ID or ASD diagnosis.
However, schematic representation of the clinical features of
our 17 patients, ordered by the position of the mutation on the
gene (figure 3), revealed that the epilepsy of patients with muta-
tions in exons 4–5 was mainly pharmacosensitive (5/6 patients),
whereas that of patients with mutations in exons 8–15 was
mainly pharmacoresistant (8/9, p=0.01).
DISCUSSION
In this study, we collected the comprehensive molecular and
clinical data of the largest series of patients with SYNGAP1
mutation so far in order to describe more accurately the neuro-
developmental and epilepsy phenotype and to address geno-
type–phenotype correlations. Delineation of the phenotype
from 36 patients with SYNGAP1 mutations showed that it
includes mild to severe ID in all, generalised epilepsy in most
and autistic behaviour in a half of them (see online supplemen-
tary table S3). In the present study, we describe the phenotype
of 17 cases with SYNGAP1-associated encephalopathy, bringing
the total number of reported patients with SYNGAP1 mutations
to 47.
Neurological examination in SYNGAP1-associated
encephalopathy
Truncal hypotonia, sometimes in association with facial hypo-
tonia, was the main recurrent feature in our patients, in line
with previous series.20 23 Likewise, ataxia, with a broad-based
or clumsy gait, was frequent in our patients and recurrently
mentioned in others.20 23 Gait abnormalities are probably due
to a combination of hypotonia, lack of global coordination,
poor motor control, inattentiveness and orthopaedic issues.
Occipitofrontal circumference was normal in 78% of patients
from the literature and in 100% of ours. Though microcephaly
has been mentioned in some cases,17 20 23 it seems to be not a
common aspect in patients with SYNGAP1 mutations.
As with previously reported patients, MRI in our patients
showed either no or nonspecific features, implying that brain
imaging is not helpful in the diagnosis of SYNGAP1-related
disorders.
The neurodevelopmental phenotype in SYNGAP1-associated
encephalopathy
In our series as well as in the literature, early motor delay with
severe language impairment is the first manifestation of
SYNGAP1 encephalopathy. Fourteen patients of our series
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acquired a few words between 1 and 4 years old but only three
patients were able to speak simple sentences, which is likely
related to ID. These data highlight that language acquisition in
most patients with SYNGAP1 mutation rapidly reaches a
plateau. It may even be subjected to regression since seven of
our patients acquired a few words but eventually lost them
again during the first years of life.
Slowing of global development and seizures appeared to
occur concurrently in some patients, suggesting that SYNGAP1
mutation might be a cause of EE, as previously suggested.18 By
definition, EE is an epilepsy disorder in which the “epileptic
activity itself may contribute to severe cognitive and behavioral
impairments above and beyond what might be expected from
the underlying pathology alone”.34 The concept of EE may
apply to specific syndromes (West syndrome and LGS) usually
associated with ID or to epileptic individuals with an encephalo-
pathic course.34 West syndrome and LGS were not diagnosed in
our patients. However, retrospective analysis of the clinical
Figure 1 Summary of SYNGAP1 mutations identified in this study and the literature. (A) Location of mutations on the different SYNGAP1 isoforms.
Mutations in red correspond to the patients identified in this study. Mutations in black correspond to previously published patients. Recurrent
mutations are underlined. Isoform 1 corresponds to the longest isoform (NM_006772.2, N-terminus: SYNGAP A, C-terminus: SYNGAP α2); isoform 2
is obtained through alternative splicing of exons 18 and 19 and differs in its C-terminus (SYNGAP β: 1265–1343: RLMLVEEELR…NGEFRNTADH
→SPSLQADAGGGGAAPGPPRHG); isoform 3 is obtained through alternative transcription start site usage involving an additional exon and differs in
its N-terminus (SYNGAP B: 1–98: MSRSRASIHR…PVEGRPHGEH→MGLRPPTPSP…RRCSSCCFPG); isoform 4 is obtained through alternative splicing of
exon 19 and differs in its C-terminus (SYNGAP γ: 1296–1343: ERQLPPLGPTNPRV…LQITENGEFRNTADH→LLIR). Isoform 5 corresponds to a rat
isoform obtained through transcription start site usage (SYNGAP C); its existence in humans has not been demonstrated and therefore remains
putative. Note that other isoforms, not represented on this schematic, have been described in rodents but not yet in humans, in particular isoform α
1, which differs in the C-terminus (QTRV). (B) Schematic representation of the mutations (above) and the variants present in the Exome Aggregation
(ExAc) database (below) on the longest SYNGAP1 isoform (NM_006772.2) and corresponding protein domains.
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Table 2 Epilepsy features in SYNGAP1-related encephalopathy
Patient ID 1 2 3 4 5 6 7 8 9
Age at seizure onset 24 months 24 months 22 months 4 years 3 years 30 months 5 years 33 months 30 months
Seizure type at onset Myoclonic jerks
(falls)
Drop attacks Febrile seizure GTCS, abs. Tonic febrile and afebrile,
myoclonic jerks











Abs. Head falls, massive myoclonic
jerks of arms, myoclonic abs.
Abs. Abs. Abs. Myoclonic jerks
(mainly arms)
Epilepsy syndrome EMA MAE then atypical
GGE
Unclassified GGE Unclassified GGE with
absences










Febrile seizures No Yes Yes No Rare No No No No
Status epilepticus No No No No No No No No No




Daily -> one per
week-> almost
seizure free
1–2/month Seizure-free for several
years
Controlled <1/day Several/day Daily Up to 100/day
Lifetime/current
antiepileptic treatment
VPA VPA then LEV LEV VPA VPA, OXC, LTG, LEV, CBZ/VPA
+LTG
VPA, CBZ LTG VPA, LTG/LTG VPA, ETH, LEV,
CLN*, ketogenic
diet/none
Pharmacoresistant No No No No Partial No No Yes Yes
EEG












1 year: normal; 3.5 years:
generalised bursts of S, S+SW in
posterior areas; 5 years: slow
background activity,











Triggers of seizures None PS No None None None NA None Chewing, emotions
Patient ID 10 11 12 13 14 15 16 17 Summary
Age at seizure onset One seizure at
3.5 years
24 months 12 months <2 years 5 years 22 months 27 months 8 years Mean 35.4 m, median age
28.5 months, 75th centile
39 months
Seizure type at onset Non-febrile Febrile seizure Febrile seizures Astatic
seizures



















Myoclonic jerks 7, atypical
abs. 5, abs. 4, eyelid
myoclonia 3, clonic or
GTCS 3, myoclonic abs.3,
atonic 2
Epilepsy syndrome NA Unclassified GGE Unclassified GGE MAE Unclassified GGE MAE Unclassified
GGE
Unclassified Unclassified 12, MAE 3,
EMA 1
Febrile seizures No Yes Yes No No No No No Yes 4
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history of some of them may illustrate an ‘encephalopathic
course’ apparently related to frequent daily seizures. As an
example, patient #14 in whom first seizures occurred up to 100
times a day had increasing behavioural disturbances and a con-
comitant stagnation of cognitive acquisition; her language and
communication skills significantly improved once the epilepsy
was controlled. On the contrary, the epilepsy of patient #4
responded to sodium valproate alone at 4 years old but her cog-
nitive evolution was very poor at 10 years. Beyond these par-
ticular clinical histories, a global view of the epilepsy and
neurodevelopmental disorder in our series shows that the level
of ID is not related to the resistance or sensitivity of the epilepsy
to AED (figure 3). In addition, the age at first seizure does not
correlate with the resistance to AED and is not clearly linked to
the severity of ID. Finally, among the eight patients with lan-
guage regression reported here, two of them only had a con-
comitant first seizure. Epilepsy in the others started several
months or years after language regression. The contribution of
interictal EEG abnormalities to cognitive regression is theoretic-
ally possible but cannot be demonstrated since EEG were
recorded after the first seizure. Consequently, while the concept
of EE may possibly correspond to the encephalopathic course of
a subgroup of patients with pharmacoresistant epilepsy in our
series, evidence to extend this concept to SYNGAP1-related neu-
rodevelopmental disorder in general is lacking.
Epilepsy in SYNGAP1-associated encephalopathy
SYNGAP1 mutation rate was 0.74% in a large series of 940
patients with ID25 and up to 1% (5/500) in another large series of
patients with EE.18 Overall, about 85% patients with SYNGAP1
mutations had seizures. This suggests that epilepsy is extremely
common in the SYNGAP1-associated encephalopathy and that
SYNGAP1 is one of the most frequently mutated genes in patients
with ID and epilepsy. All patients in our series had generalised sei-
zures, like those reported in a previous study,20 only a few of them
also experienced focal clonic or tonic clonic seizures. Generalised
bursts of spikes, spike waves and slow waves, sometimes with an
occipital predominance, were the main recurrent EEG features in
our patients. Thus, falls and myoclonic jerks, (typical or atypical)
absences, sometimes in combination, define the most common sei-
zures types that, together with the finding of interictal generalised
and/or occipital anomalies on EEG, may guide towards the diagno-
sis of SYNGAP1mutation in patients with ID.
Though most of our patients with SYNGAP1 mutations had a
diagnosis of unclassified GGE, seizure types were suggestive of
epilepsy syndromes associated with ID, particularly EMA and
MAE, whose diagnosis has been suggested in three and one
patient(s), respectively. To our knowledge, two other patients
with EMA were found to carry a de novo genetic anomaly
affecting SYNGAP1: one with a frameshift mutation20 and
another with a gene interruption due to a balanced transloca-
tion.26 However, the sequencing of SYNGAP1 in four other
patients with EMA and in another one with MAE failed to
reveal any mutations. This result is in agreement with a previous
work in which a single SYNGAP1 mutation was identified in
three patients with EMA, 10 with MAE and 2 with LGS.20 This
suggests that SYNGAP1 mutations are relatively uncommon
causes of these epilepsy syndromes.
Photosensitivity has been mentioned in previously reported
SYNGAP1 patients,17 23 but has not been emphasised. The
fixation-off phenomenon has been described once.24 In our
series, PS as a trigger for seizure was found in half of the
patients. Parents or caregivers of four patients noticed it as sensi-
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of PS is significant since clinical PS is found in only 10% of
patients with epilepsy in the 7–19-year-old group.35 We assume
that PS may have not been detected in some of our patients
because it is an age-dependent phenomenon with a peak around
puberty; it could therefore still appear in some of them; or
because of the poor cooperation of patients during the record-
ing. These data suggest that PS, when present, might be a diag-
nostic clue from the EEG of an underlying SYNGAP1 mutation.
Genotype/phenotype correlations
Although patients with SYNGAP1 mutations show a common
core clinical picture, the phenotype is relatively variable, par-
ticularly regarding the severity of ID, pharmacoresistance and
the presence of ASD. Since SYNGAP1 is a complex gene, giving
rise to several protein isoforms with opposite effects on the glu-
tamate activation pathway, via alternative splicing and transcrip-
tion start sites,10 it was tempting to speculate that the location
of the mutation on the gene could correlate to the clinical
outcome. However, we found little correlation between the
location of the mutation and the severity of ID, epilepsy and/or
ASD. Yet, the epilepsy of patients with mutations in exons 4–5
appeared more pharmacosensitive than that of patients with
mutations in exons 8–15. Interestingly, exons 4 and 5 are not
present in SYNGAP C, an isoform obtained through alternative
promoter usage, whose existence has been demonstrated in mice
and rats. Although this isoform has not been shown to exist in
humans as well, our results suggest that it could also exist and
have a different function, as already proven for isoforms α1 and
α2, which differ in their C-terminus. Further study is necessary
to confirm this finding and decrypt the precise function of each
human SYNGAP1 isoform and its relationship with the human
pathology characteristics.
Nevertheless, the comparison of the clinical features of
patients with identical mutations revealed significant clinical dif-
ferences (see online supplementary tables S2 and S3), confirm-
ing that there is a real variability of the phenotype that depends
on other factors than the mutation itself. On the contrary,
monozygotic twins had strikingly similar phenotypes, suggesting
that these modifier factors could be of genetic origin.23
ASD in SYNGAP1-associated encephalopathy and
hypothetical consequences of SYNGAP1 mutations on brain
development
Although all patients with validated pathogenic SYNGAP1 muta-
tions reported to date had ID, only half of them had a diagnosis
of ASD (including data from the literature and our series). In
our series, the presence of autistic traits was neither limited to
patients with moderate or severe ID, nor to those with pharma-
coresistant or early-onset epilepsy. Thus, ASD, like epilepsy,
could be considered as an additional feature of the
SYNGAP1-related phenotype in the context of ID, irrespectively
of its severity, rather than an ‘isolated’ diagnosis.
This observation is in agreement with previous studies
showing that many neurodevelopmental disorders are caused by
mutations in genes encoding synaptic proteins, and more specif-
ically constituents of the PSD.36 The fact that a subset of
patients with SYNGAP1 mutations exhibit autistic behaviours
suggests that a single mutation in a synaptic gene is not suffi-
cient to cause ASD and that the genetic or epigenetic back-
ground of the patient probably plays an important role in the
occurrence of autistic features in a context of intellectual
Figure 2 EEG samples from patients exemplifying electroencephalographic findings in SYNGAP1-related encephalopathy. (A) Sample
demonstrating normalisation of paroxysmal activity by eye opening, that is, fixation-off sensitivity, in patient #2. (B) Sample showing paroxysmal
activity under photic stimulation, that is, photosensitivity, in patient #2. (C) Sample from patient #1: burst of generalised spikes concomitant of a
rapid eye deviation (fast rhythms are due to benzodiazepine therapy). (D) Sample from patient #12 showing the appearance of generalised spike
wave complexes with a low degree of bilateral synchronisation after eye closure (fixation-off phenomenon).
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development impairment. Many genes mutated in patients with
ASD and ID are linked with neuronal signalling pathways and
may alter the synaptic plasticity underlying the building, refine-
ment and consolidation of neuronal networks associated with
learning and adaptive behaviours, with the balance between
inhibitory and excitatory signals being determinant in this
process.37 38 39 Given the function of the SYNGAP1 protein in
regulating excitatory inputs downstream of NMDA receptors,
the SYNGAP1-associated encephalopathy is likely a manifest-
ation of the disruption of this balance. ASD as well other neuro-
developmental disorders could in many cases result from the
interruption or impairment of the maturation processes of neur-
onal networks that are driven by neuronal activity during a crit-
ical period of brain development.39 This scenario is particularly
relevant to the fact that the clinical and morphological conse-
quences of SYNGAP1 haploinsufficiency in mice, that is, behav-
ioural disturbances and premature dendrite elongation, are
restricted to gene disruption during a given period of brain
development.4 9 Following this hypothesis, SYNGAP1 encephal-
opathy may be regarded as an example of premature closing of
the time window for cognitive development in humans. In the
SYNGAP1-associated encephalopathy, disruption of the excita-
tory/inhibitory balance, which is also a cause of epilepsy, may
therefore prematurely end the maturation process of synapses
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